Inotuzumab ozogamicin is under clinical development by Pfizer and currently in Phase II for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia). According to GlobalData, Phase II drugs for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Inotuzumab ozogamicin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Inotuzumab ozogamicin overview
Inotuzumab ozogamicin (CMC-544, PF-5208773, Besponsa) is humanized IgG4 antibody acts as anti neoplastic agent. It is formulated as lyophilized powder concentrate for solution for intravenous infusion. Besponsa is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) which includes treatment of adults with Philadelphia chromosome positive (Ph+) as well as Philadelphia chromosome negative (Ph-) relapsed or refractory B-cell precursor ALL.
Inotuzumab ozogamicin is under development for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia globally. It was also under development for the treatment of follicular B-cell non-Hodgkin's lymphoma, indolent lymphoma, diffuse large B-cell lymphoma and aggressive non-Hodgkin’s lymphoma.
Pfizer overview
Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of Inotuzumab ozogamicin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
